Education
About Us
Working with TipRanks
Follow Us
Allakos (DE:37Z)
:37Z
37Z Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.16 - €1.38
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€25.83M
Enterprise Value€31.25M
Total Cash (Recent Filing)-$13.42M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.41
Next Earnings
May 07, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding90,203,250
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.28
Forecast
1Y Price Target
€0.31Price Target Upside27.85% Upside
Rating ConsensusHold
Number of Analyst Covering6
---
Allakos News
PremiumCompany Announcements
Allakos Announces Merger Agreement with Concentra Biosciences
PremiumCompany Announcements
Allakos Reports Q4 2024 Results Amid Strategic Shift
---
Bulls Say, Bears Say
Bulls Say
Cash ReservesThe company ended the quarter with a substantial amount of cash and equivalents.
Financial StabilityALLK reported a net income for the quarter, reflecting a stable financial position despite challenges.
Bears Say
Clinical Trial ResultsAK006 failed to demonstrate therapeutic activity vs. placebo, and that further development of AK006 is being discontinued.
Program Termination CostsThere are significant wind down costs related to shutting down the AK006 program, severance payments, and contractual payments to vendors.
Workforce ReductionThe Allakos workforce is being reduced by approximately 75%.
---
Options Prices
Currently, No data available
---
Ownership Overview
9.07% Insiders
10.53%
Mutual Funds
55.63% Other Institutional Investors
20.60% Public Companies and
Individual Investors
37Z FAQ
What was Allakos’s price range in the past 12 months?
Allakos lowest stock price was €0.16 and its highest was €1.38 in the past 12 months.
What is Allakos’s market cap?
Allakos’s market cap is €25.83M.
When is Allakos’s upcoming earnings report date?
Allakos’s upcoming earnings report date is May 07, 2025 which is in 11 days.
How were Allakos’s earnings last quarter?
Allakos released its earnings results on Mar 12, 2025. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.15 by €0.15.
Is Allakos overvalued?
According to Wall Street analysts Allakos’s price is currently Undervalued.
Does Allakos pay dividends?
Allakos does not currently pay dividends.
What is Allakos’s EPS estimate?
Allakos’s EPS estimate is -0.25.
How many shares outstanding does Allakos have?
Allakos has 90,203,250 shares outstanding.
What happened to Allakos’s price movement after its last earnings report?
Allakos reported an EPS of €0 in its last earnings report, beating expectations of -€0.15. Following the earnings report the stock price went up 2.062%.
Which hedge fund is a major shareholder of Allakos?
Currently, no hedge funds are holding shares in DE:37Z
---
Allakos Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€0.31 (27.85% Upside)
€0.31 (27.85% Upside)
Blogger Sentiment
Bearish
DE:37Z Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.72%
12-Months-Change
Fundamentals
Return on Equity
-93.54%
Trailing 12-Months
Asset Growth
-60.35%
Trailing 12-Months
Company Description
Allakos
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.
---
37Z Stock 12 Month Forecast
Average Price Target
€0.31
▲(27.85% Upside)
Technical Analysis
Best Analysts Covering 37Z
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
-15.60%
assigned a buy rating 6 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -15.60% per trade.
---